We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+26.6%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$127M
AUM Growth
–
Cap. Flow
+$107M
Cap. Flow %
84.31%
Top 10 Hldgs %
76.43%
Holding
23
New
21
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GENT
GENTIUM SPA ADS
GENT
+$22.4M
2
PCYC
PHARMACYCLICS INC
PCYC
+$14.6M
3
GERN icon
Geron
GERN
+$12M
4
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$9.02M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$5.65M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 55.85%
2 Miscellaneous 44.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GENT
1
DELISTED
GENTIUM SPA ADS
GENT
$29.2M 22.95%
+505,000
New +$22.4M
GERN icon
2
Geron
GERN
$983M
$13.2M 10.36%
+2,793,120
New +$12M
PCYC
3
DELISTED
PHARMACYCLICS INC
PCYC
$13M 10.17%
+120,000
New +$14.6M
ARIA
4
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$11.9M 9.31%
+1,670,000
New +$9.02M
NPSP
5
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$5.95M 4.67%
+205,000
New +$5.65M
OMER icon
6
Omeros
OMER
$1.39B
$5.06M 3.97%
+460,000
New +$4.44M
LAB icon
7
Standard BioTools
LAB
$256M
$5.04M 3.95%
+132,500
New +$3.9M
LGND icon
8
Ligand Pharmaceuticals
LGND
$5.67B
$4.86M 3.82%
+144,270
New +$4.7M
CEMP
9
DELISTED
Cempra, Inc.
CEMP
$4.75M 3.72%
+365,000
New +$4.42M
CSII
10
DELISTED
Cardiovascular Systems, Inc.
CSII
$4.46M 3.5%
+135,000
New +$3.93M
NUWE icon
11
Nuwellis
NUWE
$3.14M
– –
0
– –
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.64M 2.86%
+56,900
New +$3.29M
NSPR icon
13
InspireMD
NSPR
$41.6M
– –
0
– –
NVDQ
14
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.85M 2.24%
+167,600
New +$2.78M
CPRX
15
DELISTED
Catalyst Pharmaceutical
CPRX
$2.64M 2.07%
+1,353,900
New +$2.74M
CELGZ
16
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$2.24M 1.76%
+800,000
New +$2.24M
BIND
17
DELISTED
BIND THERAPEUTICS INC
BIND
$2.12M 1.67%
+155,000
New +$1.97M
BLRX
18
BioLineRX
BLRX
$12.1M
$2.07M 1.62%
+1,188
New +$1.91M
TTPH
19
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2M 1.57%
+7,675
New +$1.83M
INFI
20
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.67M 1.31%
+130,000
New +$1.84M
MDVN
21
DELISTED
MEDIVATION, INC.
MDVN
$1.6M 1.26%
+50,000
New +$1.51M
KBIO
22
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$1.17M 0.92%
+35,625
New +$1.19M
CPXX
23
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$961K 0.75%
+310,000
New +$1.06M

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2013 Portfolio in Review

Q4 2013 is the first quarter with a 13F filing on record for Opaleye Management, which disclosed 23 positions worth $127M. Its ten largest holdings account for 76% of the portfolio.

Its largest position is GENTIUM SPA ADS: 505,000 shares worth $29.2M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, followed by Miscellaneous.

  • Opaleye Management's largest Q4 2013 buy was GENTIUM SPA ADS: 505,000 shares worth $29.2M.
  • Opaleye Management's ten largest holdings make up 76% of its $127M portfolio in Q4 2013.
  • Opaleye Management disclosed 23 positions in Q4 2013, its first 13F filing on record.

Based on Opaleye Management's 13F filing for Q4 2013, filed 14 Feb 2014.